MedTrace Logo

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

NCT01189812 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-08-24

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

Conditions

Interventions

DRUG

Lithium Carbonate

300 mg one time per day for 4 weeks

DRUG

Placebo

Take one time daily for 4 weeks

DRUG

Citalopram

All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)

Sponsors & Collaborators

  • Columbia Northwest Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Arifulla Khan, MD · Northwest Clinical Research Center

  • Vishaal Mehra, MD · Aretmis Institute for Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189812 on ClinicalTrials.gov